Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

VSTM - Verastem, Inc. Последние новости | Finranks

Home

VSTM

V

Verastem, Inc. (VSTM)

NCM – Цена в реальном времени. Валюта: USD

5.04

-0.25 (-4.73%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

5.10

+0.06 (1.19%)

После закрытия: Mar 27, 2026, 5:50 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.

Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play

Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play

Verastem (VSTM) maintains a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Company received FDA guidance to initiate registration-directed phase 2 trials for VS-7375 in KRAS G12D-mutated PDAC, NSCLC, and CRC. Upcoming 2026 milestones include pivotal data from RAMP 205 [PDAC], long-term RAMP 201 [LGSOC] results, and early VS-7375 data.

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held April 17-22, 2026, in San Diego, CA. “Preclinical data accepted for presentation at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics and the.

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term AVMAPKI™ FAKZYNJA™ combination therapy (avutometinib capsules; defactinib tablets) data from the Phase 2 RAMP 201 clinical trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancers. Additional abstracts accepted for presentation will also be shar.

Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?

Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?

The mean of analysts' price targets for Verastem (VSTM) points to a 159.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript

Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript

Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript

Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates

Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates

Verastem (VSTM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.33 per share a year ago.

Видео

No Data

There is no data to display